Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651790 | 0.81 | GSK3A (0.62) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL6293317 | 0.81 | KMT2A (0.73) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL29234520 | 0.79 | GSK3A (0.69) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL7263122 | 0.79 | GSK3A (0.69) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL5311390 | 0.79 | GSK3A (0.69) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL8320050 | 0.79 | SMN1; SMN2 (0.73) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL3318940 | 0.79 | GSK3A (1.00) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL30953279 | 0.77 | GSK3A (0.71) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL4455461 | 0.76 | GSK3A (0.69) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL6407514 | 0.75 | MEN1 (0.64) | GSK3AGSK3BKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| CN-105859639-A | NOVEL ANTI-INFLAMMATORY AGENTS | 雷斯韦洛吉克斯公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| CN-102427813-A | Novel anti-inflammatory agents | RESVERLOGIX CORP | 2012-04-25 | — | — | CN | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| US-6667334-B1 | Inhibitors of adhesion and migration of leukocytes and/or antagonists of adhesion receptor VLA-4 belonging to integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | GSK3A 1226/4885GSK3B 1060/4885KMT2A 4037/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | GSK3A 1424/4885GSK3B 1171/4885KMT2A 3826/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | GSK3A 1094/4885GSK3B 867/4885KMT2A 199/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | GSK3A 1226/4885GSK3B 1060/4885KMT2A 4037/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | GSK3A 1226/4885GSK3B 1060/4885KMT2A 4037/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | GSK3A 1226/4885GSK3B 1060/4885KMT2A 4037/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | GSK3A 1424/4885GSK3B 1171/4885KMT2A 3826/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | GSK3A 1424/4885GSK3B 1171/4885KMT2A 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.